We hypothesize that intermittent rapamycin dosing paired with timed protein intake creates windows for DNA repair while preserving the low‑damage accrual benefits of mTOR inhibition.

Rapamycin’s suppression of mTORC1 impairs homologous recombination and non‑homologous end joining, reducing BRCA1/Rad51 recruitment and leaving γ‑H2AX foci unresolved [1]. This repair block occurs because mTORC1 activity is required for the synthesis of repair factors and for chromatin remodeling that facilitates strand invasion. However, cells naturally alternate between growth and repair phases; homologous recombination is most active during S and G2 phases when sister chromatids are available. If rapamycin withdrawal is aligned with these phases, the transient rise in mTORC1 activity can restore translation of repair proteins without triggering a sustained anabolic state.

A short pulse of leucine‑rich protein (or a balanced meal) after rapamycin washout spikes mTORC1 signaling for 2–4 hours, enough to boost RAD51 and BRCA1 levels, promote autophagy‑dependent clearance of damaged mitochondria, and then rapamycin re‑administration returns the system to a low‑translation, anti‑inflammatory mode [2][3]. The cycle therefore mimics a natural feast‑fast rhythm: famine‑like signaling limits damage accrual, while brief feasts permit repair.

Testable predictions:

• Mice receiving rapamycin five days on, two days off with a protein‑rich meal on the off days will show faster γ‑H2AX resolution after irradiation compared with continuously dosed mice, while maintaining similar or improved survival curves [4].
• Liver and brain tissue from the intermittent regimen will exhibit higher RAD51 foci counts in S/G2 markers and lower p‑S6K levels during rapamycin phases.
• Healthspan metrics (grip strength, glucose tolerance) will be superior in the cyclic group, falsifying the hypothesis if no improvement is seen.

Falsifiability: If intermittent rapamycin plus protein pulses fails to enhance repair marker clearance or does not extend lifespan relative to continuous dosing, the core claim that timed mTORC1 reactivation uncouples longevity signaling from repair suppression is disproven.